ArticleKorean journal of ophthalmology : KJO2017
Efficacy and Safety of Intracameral Bevacizumab for Treatment of Neovascular Glaucoma.
Article in Korean journal of ophthalmology : KJO, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- The efficacy and safety of anti-vascular endothelial growth factor combined with Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a systematic review and meta-analysis.Frontiers in medicine · 2024Pooled it
- Anti-vascular endothelial growth factor for neovascular glaucoma.The Cochrane database of systematic reviews · 2023Pooled it
- Combined anti-VEGF approach in neovascular glaucoma: clinical outcomes of intracameral and intravitreal bevacizumab administration.BMC ophthalmology · 2026Article
- Advances and Challenges in Wearable Glaucoma Diagnostics and Therapeutics.Bioengineering (Basel, Switzerland) · 2024Review
- Factors Affecting the Results of Ahmed Glaucoma Valve Implantation in Diabetic Neovascular Glaucoma With or Without Previous Pars Plana Vitrectomy.Beyoglu eye journal · 2024Article
- A Review of Neovascular Glaucoma: Etiology, Pathogenesis, Diagnosis, and Treatment.Medicina (Kaunas, Lithuania) · 2022Review
- [Ocular ischemic syndrome : An important differential diagnosis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Article
- Presentation, etiology and treatment outcome of neovascular glaucoma in Ekiti state, South Western Nigeria.African health sciences · 2021Article
- Role of bevacizumab intraocular injection in the management of neovascular glaucoma.International journal of ophthalmology · 2021Article
- Anti-vascular endothelial growth factor for neovascular glaucoma.The Cochrane database of systematic reviews · 2020Review
- What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study.BMC ophthalmology · 2019Article
- The effect on wound healing of pazopanib and bevacizumab compared with corticosteroid in experimental glaucoma filtration surgery.International journal of ophthalmology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the long-term efficacy and safety of intracameral bevacizumab in patients with neovascular glaucoma.
methodsThis retrospective study included 26 eyes of 26 neovascular glaucoma patients who received intracameral bevacizumab injection between January 2013 and May 2015, and were followed-up for at least 1 year. All patients were treated with topical and/or systemic intraocular pressure (IOP)-lowering medications, intracameral bevacizumab, and panretinal photocoagulation (PRP). The main outcome measures were changes in visual acuity, IOP, and neovascularization of the iris (NVI) and the anterior chamber angle (NVA). To assess the safety of intracameral bevacizumab, corneal endothelial changes were also determined using specular microscopy. Patients whose IOP was uncontrolled received IOP-lowering surgery. Clinical factors associated with IOP-lowering surgery were also investigated.
resultsIn all patients, intracameral bevacizumab resulted in a rapid and marked reduction of IOP, NVI, and NVA within 1 week. At 12 months after initial injection, 19 of 26 eyes (73%) underwent IOP-lowering surgery. The average interval between initial injection and surgical treatment was 33.6 ± 26.9 days. Baseline IOP (p = 0.018), NVA grade (p = 0.029), and incomplete PRP (p = 0.005) were identified as predictive factors for IOP-lowering surgery. During the follow-up period, there were no statistically significant corneal endothelial changes after intracameral bevacizumab injection.
conclusionsDuring 1 year of follow-up after intracameral bevacizumab, the procedure was found to be safe for the corneal endothelium. However, the IOP-lowering effect was transient, and 73% of patients eventually required IOP-lowering surgery. Predictive factors for IOP-lowering surgery were high baseline IOP and NVA grade, and incomplete PRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.